查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1871935

全球個人化微生物組療法市場預測（至2032年）－按療法類型、給藥途徑、技術、應用、最終用戶和地區分類的分析

Personalized Microbiome Therapeutics Market Forecasts to 2032 - Global Analysis By Therapy Type, Route of Administration, Technology, Application, End User, and By Geography.
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的一項研究，全球個人化微生物組療法市場預計到 2025 年價值 2.5 億美元，到 2032 年達到 10.5 億美元，在預測期內以 22.7% 的複合年成長率成長。

個人化微生物組治療方法是根據個體獨特的微生物組特徵，客製化地調節其腸道、皮膚或其他部位的微生物組。透過分析微生物組的組成和功能，可以利用益生菌、益生元、合益素或微生物群落來調整治療方法，進而恢復菌叢平衡、預防疾病並改善健康。這種精準的方法利用了微生物組科學、基因組學和人工智慧領域的最新進展，能夠針對消化器官系統、免疫系統、代謝系統和神經系統疾病進行標靶干預。

根據 CellPress 報道，這些公司正在開發客製化益生菌複合物，旨在與個人的腸道菌群相匹配，他們聲稱這種複合物可以比頻譜替代療法更有效地治療發炎性腸道疾病 (IBD) 等疾病。

人們對腸道健康療法的興趣日益濃厚

隨著消費者對維護消化系統健康和預防慢性疾病的關注度日益提高，全球對腸道健康療法的需求正在飆升。在精準醫療日益發展的趨勢下，個人化微生物組療法正受到越來越多的關注，精準醫療強調透過調節微生物組來治療代謝性疾病、神經系統疾病和自體免疫疾病。越來越多的科學證據顯示腸-腦軸和腸-免疫軸的存在，這進一步加速了該療法的應用。此外，不斷擴展的臨床試驗計畫以及生物技術新興企業與大型製藥公司之間的合作也推動了這一成長。這一趨勢使微生物組療法成為醫療保健領域變革性的前沿領域。

複雜的監管核准流程

由於生物治療產品和基因介入藥物的法規結構十分嚴格，市場面臨許多障礙。基於微生物組的藥物核准流程在不同地區仍不明確，導致商業化進程延緩。不同監管機構（例如FDA和EMA）在安全性和有效性標準上的差異，進一步加劇了複雜性。此外，缺乏臨床證據和標準化的生產通訊協定也阻礙了研發進展。這些障礙推高了研發成本，延長了產品上市時間，限制了市場擴充性，儘管該領域具有強大的創新潛力。

微生物基因定序技術的進步

次世代定序技術使研究人員能夠以前所未有的精確度解讀個體微生物組。這項技術進步使得針對患者微生物譜量身定做的精準標靶治療方案成為可能。人工智慧和生物資訊學的日益融合正在增強微生物行為的預測模型。此外，定序成本的下降擴大了臨床研究和診斷的覆蓋範圍。這些進展為個人化治療模式鋪平了道路，拓寬了微生物組調節療法的臨床應用。

長期療效數據尚不確定

儘管早期臨床試驗顯示出令人鼓舞的結果，但有限的縱向研究對基於微生物組的療法的持續療效提出了質疑。宿主反應和微生物組穩定性的差異引發了人們對療效可重複性和一致性的擔憂。此外，缺乏明確的治療成功生物標記也使治療後評估變得複雜。隨著其他治療方法的不斷發展，對療效持續性的質疑可能會阻礙其廣泛應用。在獲得可靠的多年療效數據以支持臨床可信度和市場永續性之前，投資者和醫療服務提供者仍將保持謹慎。

新冠疫情的影響：

新冠疫情凸顯了免疫力與腸道環境之間的聯繫，並加速了透過調節腸道菌叢來增強免疫力的研究。然而，封鎖措施擾亂了臨床試驗和微生物培養供應鏈。疫情後的恢復期重新燃起了人們對益生菌和以腸道菌叢標靶治療的興趣。大眾對個人化醫療解決方案的認知度提高，也促進了臨床合作。因此，新冠疫情既是暫時的干擾因素，也是推動以腸道菌叢為中心的創新發展的催化劑。

預計在預測期內，生物治療產品領域將佔據最大的市場佔有率。

由於生物製劑能夠直接調節宿主微生物群，並在治療復發性困難梭狀芽孢桿菌傳染病、發炎性腸道疾病和代謝紊亂方面展現出顯著療效，預計在預測期內，生物製劑將佔據最大的市場佔有率。 VOWST 和 REBYOTA 等產品的監管核准進一步佐證了該領域的有效性。生物製劑能夠恢復微生物平衡並發揮標靶作用，使其成為個人化醫療應用的理想選擇。不斷成長的臨床應用、日益擴大的適應症以及強大的研發管線，已使生物製藥成為市場的基礎性組成部分。

預計在預測期內，直腸和灌腸給藥途徑將呈現最高的複合年成長率。

由於直腸和灌腸給藥途徑在局部腸道菌群重建方面具有卓越的療效，預計在預測期內，該途徑將實現最高的成長率。這種給藥途徑避免了胃酸分解，確保了活性微生物的高存活率。它尤其適用於治療潰瘍性大腸炎和復發性困難梭狀芽孢桿菌傳染病等下消化道疾病。製劑技術的創新和患者友善裝置的出現正在提高其接受度。隨著臨床證據的積累，直腸給藥作為​​一種精準靶向的微生物組療法，因其起效迅速且全身暴露量極低而日益受到認可。

佔比最大的地區：

由於胃腸道疾病盛行率不斷上升以及人們對預防性醫療保健的日益關注，亞太地區預計將在預測期內佔據最大的市場佔有率。中國、日本和印度等國家正在加大對微生物組研究和個人化醫療的投入。不斷完善的醫療基礎設施、有利的監管改革以及消費者對腸道健康日益成長的意識正在推動相關技術的普及。在地化生產能力和策略合作夥伴關係將進一步增強市場滲透率，使亞太地區成為關鍵的成長區域。

複合年成長率最高的地區：

在預測期內，北美預計將實現最高的複合年成長率，這主要得益於先進的研發、完善的臨床試驗基礎設施以及早期監管核准。美國在微生物組領域擁有豐富的研發管線、學術合作和創業投資，引領創新。對個人化治療日益成長的需求、與數位健康平台的整合以及有利的報銷政策正在加速該領域的應用。策略性收購以及VOWST和REBYOTA等獲得FDA核准的產品正在增強市場勢頭，使北美成為微生物組療法的創新中心。

免費客製化服務：

訂閱本報告的用戶可從以下免費自訂選項中選擇一項：

  • 公司簡介
    • 對最多三家其他公司進行全面分析
    • 對主要企業進行SWOT分析（最多3家公司）
  • 區域分類
    • 根據客戶興趣對主要國家進行市場估算、預測和複合年成長率分析（註：基於可行性檢查）
  • 競爭基準化分析
    • 基於產品系列、地域覆蓋和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 引言

  • 概述
  • 相關利益者
  • 分析範圍
  • 分析方法
  • 分析材料

第3章 市場趨勢分析

  • 促進要素
  • 抑制因素
  • 機會
  • 威脅
  • 技術分析
  • 應用分析
  • 終端用戶分析
  • 新興市場
  • 新冠疫情的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代產品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球個人化微生物組療法市場（依療法類型分類）

  • 活體生物製藥
  • 糞便微生物移植（FMT）
  • 人工益生菌
  • 基於噬菌體的治療方法
  • 後生元製劑
  • 合益素組合

6. 全球個人化微生物組療法市場（依給藥途徑分類）

  • 口服膠囊
  • 直腸/灌腸給藥
  • 鼻腔和吸力系統
  • 注射劑型
  • 經皮給藥
  • 封裝微生物凝膠

7. 全球個人化微生物組療法市場（依技術分類）

  • 總體基因體學定序
  • 人工智慧驅動的微生物組圖譜繪製
  • CRISPR基因編輯
  • 單細胞分析
  • 多體學整合
  • 機器學習治療設計

8. 全球個人化微生物組療法市場（按應用分類）

  • 胃腸道疾病
  • 代謝性疾病
  • 神經系統疾病
  • 免疫相關疾病
  • 癌症免疫療法支持
  • 心血管健康

9. 全球個人化微生物組療法市場（依最終用戶分類）

  • 醫院和診所
  • 製藥公司
  • 實驗室
  • 生技Start-Ups
  • CMO（合約生產組織）
  • 學術機構

10. 全球個人化微生物組療法市場（按地區分類）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 亞太其他地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章：主要趨勢

  • 合約、商業夥伴關係和合資企業
  • 企業合併（M&A）
  • 新產品上市
  • 業務拓展
  • 其他關鍵策略

第12章：公司簡介

  • Seres Therapeutics
  • Finch Therapeutics
  • Ferring Pharmaceuticals
  • Rebiotix
  • Synlogic
  • 4D Pharma
  • Enterome
  • Bacthera
  • Vedanta Biosciences
  • Astellas
  • BioMe
  • Nestle Health Science
  • Takeda
  • Pfizer
  • Evelo Biosciences
  • Kirin Holdings
  • GSK
Product Code: SMRC32305

According to Stratistics MRC, the Global Personalized Microbiome Therapeutics Market is accounted for $250 million in 2025 and is expected to reach $1050 million by 2032 growing at a CAGR of 22.7% during the forecast period. Personalized Microbiome Therapeutics are customized treatments designed to modulate an individual's gut, skin, or other microbiomes based on their unique profile. By analyzing microbiota composition and function, therapies are tailored-using probiotics, prebiotics, synbiotics, or microbial consortia-to restore balance, prevent disease, and enhance health outcomes. This precision approach leverages advances in microbiome science, genomics, and AI to enable targeted interventions for digestive, immune, metabolic, and neurological disorders.

According to Cell Press, companies are developing bespoke probiotic consortia, engineered for an individual's gut flora, to treat conditions like IBD more effectively than broad-spectrum alternatives.

Market Dynamics:

Driver:

Rising interest in gut-health therapies

Growing consumer focus on digestive wellness and chronic disease prevention, the demand for gut-health therapeutics is surging globally. Personalized microbiome therapies are gaining traction as precision medicine initiatives emphasize microbiota modulation for metabolic, neurological, and autoimmune disorders. Increasing scientific validation of gut-brain and gut-immune axes further accelerates adoption. Moreover, expanding clinical trial pipelines and collaborations between biotech startups and pharma giants amplify growth. This trend positions microbiome therapeutics as a transformative healthcare frontier.

Restraint:

Complex regulatory approval pathways

The market faces significant hurdles due to stringent regulatory frameworks surrounding live biotherapeutic products and genetic interventions. Approval pathways for microbiome-based drugs remain ambiguous across regions, delaying commercialization. Variations in safety and efficacy standards between regulatory bodies like FDA and EMA add complexity. Additionally, limited clinical evidence and lack of standardized manufacturing protocols slow progression. These barriers elevate development costs and prolong product timelines, restraining market scalability despite strong innovation potential.

Opportunity:

Advancements in microbial gene sequencing

Next-generation sequencing technologies, researchers can now decode individual microbiomes with unprecedented accuracy. This technological evolution enables precision-targeted therapeutic formulations customized to patients' microbial profiles. Growing integration of AI and bioinformatics enhances predictive modeling of microbial behavior. Furthermore, decreasing costs of sequencing expand accessibility for clinical research and diagnostics. Such advancements pave the way for personalized treatment paradigms and broaden the clinical applications of microbiome modulation therapies.

Threat:

Uncertain long-term efficacy data

Despite early clinical promise, limited longitudinal studies challenge the confidence in durable outcomes of microbiome-based treatments. Variability in host response and microbiota stability raises concerns over reproducibility and consistency. Moreover, absence of clear biomarkers for therapeutic success complicates post-treatment evaluation. As competing interventions evolve, skepticism over lasting benefits could slow adoption. Investors and healthcare providers remain cautious until robust, multi-year efficacy data validate clinical dependability and market sustainability.

Covid-19 Impact:

The pandemic underscored the link between immunity and gut health, boosting research in microbiome modulation for immune resilience. However, lockdowns disrupted clinical trials and supply chains for microbial cultures. Post-pandemic recovery reignited interest in probiotic and microbiota-targeted therapies for respiratory and inflammatory conditions. Increased public awareness of personalized health solutions accelerated clinical collaborations. Consequently, COVID-19 served as both a temporary disruptor and a catalyst for microbiome-focused innovation.

The live biotherapeutic products segment is expected to be the largest during the forecast period

The live biotherapeutic products segment is expected to account for the largest market share during the forecast period, due to their direct modulation of host microbiota and proven efficacy in treating recurrent C. difficile, IBD, and metabolic disorders. Products like VOWST and REBYOTA have gained regulatory traction, validating the segment. Their ability to restore microbial balance and deliver targeted benefits makes them ideal for personalized applications. Growing clinical adoption, expanding indications, and robust pipelines position live biotherapeutics as the market's foundational segment.

The rectal & enema delivery segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the rectal & enema delivery segment is predicted to witness the highest growth rate, driven by its superior efficacy in localized gut microbiota restoration. This route bypasses gastric degradation, ensuring higher viability of live microbes. It's particularly effective for lower GI conditions like ulcerative colitis and recurrent C. difficile. Innovations in formulation and patient-friendly devices are improving acceptance. As clinical evidence grows, rectal delivery is gaining favor for precision-targeted microbiome therapies with rapid onset and minimal systemic exposure.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, rising prevalence of GI disorders, and growing interest in preventive health. Countries like China, Japan, and India are investing in microbiome research and personalized medicine. Expanding healthcare infrastructure, supportive regulatory reforms, and increasing consumer awareness of gut health are driving adoption. Local manufacturing capabilities and strategic partnerships further enhance market penetration, making Asia Pacific a key growth region

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR supported by advanced R&D, strong clinical trial infrastructure, and early regulatory approvals. The U.S. leads in microbiome innovation, with robust pipelines, academic collaborations, and venture capital investment. Growing demand for personalized therapies, integration with digital health platforms, and favorable reimbursement policies accelerate adoption. Strategic acquisitions and FDA-approved products like VOWST and REBYOTA reinforce market momentum, positioning North America as the innovation epicenter for microbiome therapeutics

Key players in the market

Some of the key players in Personalized Microbiome Therapeutics Market include Seres Ther, Finch Ther, Ferring Ph, Rebiotix, Synlogic, 4D Pharma, Enterome, Bacthera, Vedanta B, Astellas, BioMe, Nestle He, Takeda, Pfizer, Evelo Bios, Kirin Hold, GSK.

Key Developments:

In October 2025, Seres Therapeutics launched an upgraded version of its microbiome analysis platform, improving the accuracy of predicting patient response to its lead product, SER-109. The update supports real-time strain selection for a next-generation, personalized formulation for recurrent C. difficile infection, enhancing remission rates.

In July 2025, Finch Therapeutics released new data and a corresponding diagnostic algorithm for its CP101 product in recurrent C. difficile, identifying key predictive microbial markers of success. This AI-based tool allows clinicians to stratify patients most likely to benefit, paving the way for a more targeted treatment approach.

In June 2025, Takeda enhanced its "GI-Discover" platform with advanced metagenomic sequencing and machine learning models to identify novel microbiome-derived targets for ulcerative colitis. The update supports faster patient stratification for its clinical trials and the development of companion diagnostics.

Therapy Types Covered:

  • Live Biotherapeutic Products
  • Fecal Microbiota Transplant (FMT)
  • Engineered Probiotics
  • Phage-Based Therapies
  • Postbiotic Formulations
  • Synbiotic Combinations

Route Of Administrations Covered:

  • Oral Capsules
  • Rectal & Enema Delivery
  • Nasal & Inhalation Systems
  • Injectable Formats
  • Transdermal Delivery
  • Encapsulated Microbiome Gels

Technologies Covered:

  • Metagenomics Sequencing
  • AI-Driven Microbiome Mapping
  • CRISPR Gene Editing
  • Single-Cell Analysis
  • Multi-Omics Integration
  • Machine Learning Therapeutic Design

Applications Covered:

  • Gastrointestinal Disorders
  • Metabolic Diseases
  • Neurological Disorders
  • Immune-Related Conditions
  • Cancer Immunotherapy Support
  • Cardiovascular Health

End Users Covered:

  • Hospitals & Clinics
  • Pharmaceutical Companies
  • Research Laboratories
  • Biotech Startups
  • Contract Manufacturing Organizations
  • Academic Institutes

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Personalized Microbiome Therapeutics Market, By Therapy Type

  • 5.1 Introduction
  • 5.2 Live Biotherapeutic Products
  • 5.3 Fecal Microbiota Transplant (FMT)
  • 5.4 Engineered Probiotics
  • 5.5 Phage-Based Therapies
  • 5.6 Postbiotic Formulations
  • 5.7 Synbiotic Combinations

6 Global Personalized Microbiome Therapeutics Market, By Route of Administration

  • 6.1 Introduction
  • 6.2 Oral Capsules
  • 6.3 Rectal & Enema Delivery
  • 6.4 Nasal & Inhalation Systems
  • 6.5 Injectable Formats
  • 6.6 Transdermal Delivery
  • 6.7 Encapsulated Microbiome Gels

7 Global Personalized Microbiome Therapeutics Market, By Technology

  • 7.1 Introduction
  • 7.2 Metagenomics Sequencing
  • 7.3 AI-Driven Microbiome Mapping
  • 7.4 CRISPR Gene Editing
  • 7.5 Single-Cell Analysis
  • 7.6 Multi-Omics Integration
  • 7.7 Machine Learning Therapeutic Design

8 Global Personalized Microbiome Therapeutics Market, By Application

  • 8.1 Introduction
  • 8.2 Gastrointestinal Disorders
  • 8.3 Metabolic Diseases
  • 8.4 Neurological Disorders
  • 8.5 Immune-Related Conditions
  • 8.6 Cancer Immunotherapy Support
  • 8.7 Cardiovascular Health

9 Global Personalized Microbiome Therapeutics Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals & Clinics
  • 9.3 Pharmaceutical Companies
  • 9.4 Research Laboratories
  • 9.5 Biotech Startups
  • 9.6 Contract Manufacturing Organizations
  • 9.7 Academic Institutes

10 Global Personalized Microbiome Therapeutics Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Seres Therapeutics
  • 12.2 Finch Therapeutics
  • 12.3 Ferring Pharmaceuticals
  • 12.4 Rebiotix
  • 12.5 Synlogic
  • 12.6 4D Pharma
  • 12.7 Enterome
  • 12.8 Bacthera
  • 12.9 Vedanta Biosciences
  • 12.10 Astellas
  • 12.11 BioMe
  • 12.12 Nestle Health Science
  • 12.13 Takeda
  • 12.14 Pfizer
  • 12.15 Evelo Biosciences
  • 12.16 Kirin Holdings
  • 12.17 GSK

List of Tables

  • Table 1 Global Personalized Microbiome Therapeutics Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Personalized Microbiome Therapeutics Market Outlook, By Therapy Type (2024-2032) ($MN)
  • Table 3 Global Personalized Microbiome Therapeutics Market Outlook, By Live Biotherapeutic Products (2024-2032) ($MN)
  • Table 4 Global Personalized Microbiome Therapeutics Market Outlook, By Fecal Microbiota Transplant (FMT) (2024-2032) ($MN)
  • Table 5 Global Personalized Microbiome Therapeutics Market Outlook, By Engineered Probiotics (2024-2032) ($MN)
  • Table 6 Global Personalized Microbiome Therapeutics Market Outlook, By Phage-Based Therapies (2024-2032) ($MN)
  • Table 7 Global Personalized Microbiome Therapeutics Market Outlook, By Postbiotic Formulations (2024-2032) ($MN)
  • Table 8 Global Personalized Microbiome Therapeutics Market Outlook, By Synbiotic Combinations (2024-2032) ($MN)
  • Table 9 Global Personalized Microbiome Therapeutics Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 10 Global Personalized Microbiome Therapeutics Market Outlook, By Oral Capsules (2024-2032) ($MN)
  • Table 11 Global Personalized Microbiome Therapeutics Market Outlook, By Rectal & Enema Delivery (2024-2032) ($MN)
  • Table 12 Global Personalized Microbiome Therapeutics Market Outlook, By Nasal & Inhalation Systems (2024-2032) ($MN)
  • Table 13 Global Personalized Microbiome Therapeutics Market Outlook, By Injectable Formats (2024-2032) ($MN)
  • Table 14 Global Personalized Microbiome Therapeutics Market Outlook, By Transdermal Delivery (2024-2032) ($MN)
  • Table 15 Global Personalized Microbiome Therapeutics Market Outlook, By Encapsulated Microbiome Gels (2024-2032) ($MN)
  • Table 16 Global Personalized Microbiome Therapeutics Market Outlook, By Technology (2024-2032) ($MN)
  • Table 17 Global Personalized Microbiome Therapeutics Market Outlook, By Metagenomics Sequencing (2024-2032) ($MN)
  • Table 18 Global Personalized Microbiome Therapeutics Market Outlook, By AI-Driven Microbiome Mapping (2024-2032) ($MN)
  • Table 19 Global Personalized Microbiome Therapeutics Market Outlook, By CRISPR Gene Editing (2024-2032) ($MN)
  • Table 20 Global Personalized Microbiome Therapeutics Market Outlook, By Single-Cell Analysis (2024-2032) ($MN)
  • Table 21 Global Personalized Microbiome Therapeutics Market Outlook, By Multi-Omics Integration (2024-2032) ($MN)
  • Table 22 Global Personalized Microbiome Therapeutics Market Outlook, By Machine Learning Therapeutic Design (2024-2032) ($MN)
  • Table 23 Global Personalized Microbiome Therapeutics Market Outlook, By Application (2024-2032) ($MN)
  • Table 24 Global Personalized Microbiome Therapeutics Market Outlook, By Gastrointestinal Disorders (2024-2032) ($MN)
  • Table 25 Global Personalized Microbiome Therapeutics Market Outlook, By Metabolic Diseases (2024-2032) ($MN)
  • Table 26 Global Personalized Microbiome Therapeutics Market Outlook, By Neurological Disorders (2024-2032) ($MN)
  • Table 27 Global Personalized Microbiome Therapeutics Market Outlook, By Immune-Related Conditions (2024-2032) ($MN)
  • Table 28 Global Personalized Microbiome Therapeutics Market Outlook, By Cancer Immunotherapy Support (2024-2032) ($MN)
  • Table 29 Global Personalized Microbiome Therapeutics Market Outlook, By Cardiovascular Health (2024-2032) ($MN)
  • Table 30 Global Personalized Microbiome Therapeutics Market Outlook, By End User (2024-2032) ($MN)
  • Table 31 Global Personalized Microbiome Therapeutics Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 32 Global Personalized Microbiome Therapeutics Market Outlook, By Pharmaceutical Companies (2024-2032) ($MN)
  • Table 33 Global Personalized Microbiome Therapeutics Market Outlook, By Research Laboratories (2024-2032) ($MN)
  • Table 34 Global Personalized Microbiome Therapeutics Market Outlook, By Biotech Startups (2024-2032) ($MN)
  • Table 35 Global Personalized Microbiome Therapeutics Market Outlook, By Contract Manufacturing Organizations (2024-2032) ($MN)
  • Table 36 Global Personalized Microbiome Therapeutics Market Outlook, By Academic Institutes (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.